| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 8445 | 2020 |
| Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies AJ Greaney, AN Loes, KHD Crawford, TN Starr, KD Malone, HY Chu, ... Cell host & microbe, 2021 | 1213 | 2021 |
| Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift E Cameroni, JE Bowen, LE Rosen, C Saliba, SK Zepeda, K Culap, ... Nature 602 (7898), 664-670, 2022 | 1133 | 2022 |
| Sequelae in adults at 6 months after COVID-19 infection JK Logue, NM Franko, DJ McCulloch, D McDonald, A Magedson, CR Wolf, ... JAMA network open 4 (2), e210830-e210830, 2021 | 948 | 2021 |
| Multiple early factors anticipate post-acute COVID-19 sequelae Y Su, D Yuan, DG Chen, RH Ng, K Wang, J Choi, S Li, S Hong, R Zhang, ... Cell 185 (5), 881-895. e20, 2022 | 832 | 2022 |
| Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays KHD Crawford, R Eguia, AS Dingens, AN Loes, KD Malone, CR Wolf, ... Viruses 12 (5), 513, 2020 | 734 | 2020 |
| Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity E Shrock, E Fujimura, T Kula, RT Timms, IH Lee, Y Leng, ML Robinson, ... Science 370 (6520), eabd4250, 2020 | 598 | 2020 |
| Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021 SW Hanson, C Abbafati, JG Aerts, Z Al-Aly, C Ashbaugh, T Ballouz, ... Jama 328 (16), 1604-1615, 2022 | 476 | 2022 |
| Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein SJ Zost, P Gilchuk, RE Chen, JB Case, JX Reidy, A Trivette, RS Nargi, ... Nature medicine 26 (9), 1422-1427, 2020 | 474 | 2020 |
| Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 AC Walls, B Fiala, A Schäfer, S Wrenn, MN Pham, M Murphy, ... Cell 183 (5), 1367-1382. e17, 2020 | 464 | 2020 |
| The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates NI Mazur, D Higgins, MC Nunes, JA Melero, AC Langedijk, N Horsley, ... The Lancet Infectious Diseases 18 (10), e295-e311, 2018 | 444* | 2018 |
| Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation E Seydoux, LJ Homad, AJ MacCamy, KR Parks, NK Hurlburt, ... Immunity 53 (1), 98-105. e5, 2020 | 394 | 2020 |
| Distinct early serological signatures track with SARS-CoV-2 survival C Atyeo, S Fischinger, T Zohar, MD Slein, J Burke, C Loos, DJ McCulloch, ... Immunity 53 (3), 524-532. e4, 2020 | 365 | 2020 |
| Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis T Shi, A Denouel, AK Tietjen, I Campbell, E Moran, X Li, H Campbell, ... The Journal of infectious diseases 222 (Supplement_7), S577-S583, 2020 | 338 | 2020 |
| The effects of the COVID-19 pandemic on community respiratory virus activity EJ Chow, TM Uyeki, HY Chu Nature Reviews Microbiology 21 (3), 195-210, 2023 | 336 | 2023 |
| Development of a definition of postacute sequelae of SARS-CoV-2 infection T Thaweethai, SE Jolley, EW Karlson, EB Levitan, B Levy, GA McComsey, ... Jama 329 (22), 1934-1946, 2023 | 315 | 2023 |
| Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection KHD Crawford, AS Dingens, R Eguia, CR Wolf, N Wilcox, JK Logue, ... The Journal of infectious diseases 223 (2), 197-205, 2021 | 300 | 2021 |
| Cryptic transmission of SARS-CoV-2 in Washington state T Bedford, AL Greninger, P Roychoudhury, LM Starita, M Famulare, ... Science 370 (6516), 571-575, 2020 | 298 | 2020 |
| Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California X Deng, W Gu, S Federman, L Du Plessis, OG Pybus, NR Faria, C Wang, ... Science 369 (6503), 582-587, 2020 | 271 | 2020 |
| Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants M McCallum, AC Walls, KR Sprouse, JE Bowen, LE Rosen, HV Dang, ... Science 374 (6575), 1621-1626, 2021 | 256 | 2021 |
